secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001140361-24-050005
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin NAVIGATE trial: belapectin reduces varices by 48.9% in per-protocol but misses ITT primary endpoint
--------------------------------------------------------------------------------

- In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.
- In per-protocol (n=290), belapectin 2mg/kg showed 48.9% reduction in varices (p<0.05).
- Safety profile favorable; adverse events comparable across cohorts, no drug-related SAEs.
- Additional 36-month data from ~50 patients expected in Q1 2025.
- Company will engage with potential partners to determine next steps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/0001140361-24-050005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124050005/ef20040433_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-050005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer